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Summary
Background & Aims—Patients with chronic liver disease and cirrhosis have a dysregulated 
coagulation system and are prone to thrombosis. The basis for this hypercoagulable state is not 
completely understood. Tissue factor (TF) is the primary initiator of coagulation in vivo. Patients 
with cirrhosis have increased TF activity in white blood cells and circulating microparticles. The 
aim of our study was to determine the contribution of TF to the hypercoagulable state in a mouse 
model of chronic liver injury.
Methods—We measured levels of TF activity in the liver, white blood cells and circulating 
microparticles, and a marker of activation of coagulation [thrombinantithrombin complexes 
(TATc)] in the plasma of mice subjected to bile duct ligation for 12 days. We used wild-type mice, 
mice with a global TF deficiency (low TF mice), and mice deficient for TF in either myeloid cells 
(TFflox/flox, LysMCre mice) or in hepatocytes (TFflox/flox, AlbCre).
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Results—Wild-type mice with liver injury had increased levels of white blood cell, microparticle 
TF activity and TATc compared to sham mice. Low TF mice and mice lacking TF in hepatocytes 
had reduced levels of TF in the liver and in microparticles and exhibited reduced activation of 
coagulation without a change in liver fibrosis. In contrast, mice lacking TF in myeloid cells had 
reduced white blood cell TF but no change in microparticle TF activity or TATc.
Conclusions—Hepatocyte TF activates coagulation in a mouse model of chronic liver injury. 
TF may contribute to the hypercoagulable state associated with chronic liver diseases in patients.
Keywords
Liver injury; coagulation; microparticle; thrombosis
Introduction
Patients with chronic liver disease, and particularly cirrhosis, have a dysregulated 
coagulation system [1–2]. The traditional view of coagulation disorders in patients with 
chronic liver disease has changed from concerns about bleeding to thrombosis [1–2]. 
Routine diagnostic tests of coagulation, such as the prothrombin time and the activated 
partial thromboplastin time, are frequently prolonged in patients with chronic liver disease 
suggesting that these patients would be prone to bleeding [1–2]. However, an increasing 
number of studies indicate that these abnormal findings in routine coagulation tests do not 
necessarily predict an increased bleeding tendency in patients with chronic liver disease [1–
6]. Rather, recent findings indicate a thrombotic risk in these patients [7–10]. Likewise, 
thrombin-generation tests performed in the presence of the anticoagulant thrombomodulin or 
snake-venom extract (Protac, Pentapharm) have shown that plasma from patients with 
cirrhosis generate similar, or even greater, amounts of thrombin than plasmas from healthy 
subjects [1, 3–6]. The basis for this hypercoagulable state in patients with chronic liver 
disease is not completely understood [1–2]. It has been suggested that it may be due, in part, 
to increased levels of the procoagulant factor VIII (FVIII) and von Willebrand factor and 
reduced levels of the anticoagulant protein C and antithrombin [1–2, 11]. However, this 
hypercoagulable state is likely to be more complex than simply changes in a few proteins.
Tissue factor (TF) is the transmembrane receptor for FVII/VIIa and the TF:FVIIa complex 
functions as the primary initiator of coagulation in vivo [12]. It is essential for hemostasis. 
TF can be found in low- (also called encrypted) and high-activity (also called de-encrypted) 
states, which is thought to be due to differences in the conformation of TF [13]. TF is 
constitutively expressed by cells within and surrounding the blood vessel wall, such as 
vascular smooth muscle cells, pericytes and adventitial fibroblasts [12]. In addition, TF has 
been implicated in thrombosis associated with a variety of diseases [12, 14–16]. Several 
studies have shown that monocyte TF expression and circulating microparticle (MP) TF 
activity are increased in patients with cirrhosis [17–20]. MPs are submicron membrane 
vesicles derived from apoptotic and/or activated cells [21]. TF-positive MPs are highly 
procoagulant [21–22]. Recently, we reported that hepatocytes constitutively express TF in 
an inactive state, but this TF is rapidly activated during acute hepatocellular injury and 
activates the coagulation system [23]. The contribution of different cellular sources of TF to 
the activation of coagulation in chronic liver disease has not been evaluated.
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In this study, we investigated the role of TF in the activation of coagulation in a mouse 
model of chronic liver disease. In addition, we determined the source of TF responsible for 
the activation of coagulation. We found that TF expression by hepatocytes activates 
coagulation in this model.
Material and Methods
Mice
Wild-type C57BL/6J male mice were obtained from The Jackson Laboratory (Bar Harbor, 
ME). Transgenic low TF male mice on a C57BL/6J background were generated as 
previously described [24]. These mTF−/−, hTF+/+ mice express no mouse TF but have low 
levels of human TF expressed from a minigene (~1% of levels compared with wild-type 
mice) in all tissues [24]. Littermate controls containing the same human transgene and 
expressing either 50% (mTF+/−, hTF+/+ mice, hereafter referred to as TF+/− mice) or 100% 
of levels of murine TF (mTF+/+, hTF+/+ mice, hereafter referred to as TF+/+ mice) were used 
as controls. The generation of the TFflox/flox, lysozyme (LysM) Cre recombinase mice, 
which deletes the TF gene in myeloid cells by ~90%, has been described [15–16]. The 
generation of the TFflox/flox, AlbCre mice, with a deletion of the TF gene in hepatocytes, has 
been described [23]. Mice were fed a normal laboratory diet and given water ad libitum. All 
mouse studies were performed with the approval of the University of North Carolina at 
Chapel Hill Institutional Animal Care and Use Committee (IACUC).
Bile Duct Ligation (BDL)
Male mice between the ages of 9 and 17 weeks were anesthetized with 2.5% inhaled 
isoflurane. The abdomen was then shaved and prepared utilizing sterile technique. An 
upper-midline laparotomy incision was made, and the common bile duct was ligated with 
6-0 silk suture (Unify® sutures, AD Surgical). The muscle layer and skin were closed with 
absorbable and non-absorbable suture material, respectively (Unify® sutures, AD Surgical). 
All steps, excluding ligation of the bile duct, were performed for sham operations. Criteria 
for successful BDL at the time of animal sacrifice included jaundiced soft tissues, patchy 
liver discoloration, and biliary tree dilation. The success rate for the different BDL surgeries 
was 59%, 65%, 66%, and 75% in wild type mice, low TF mice, TFflox/flox, LysMCre and 
TFflox/flox, AlbCre mice and their respective littermate controls, respectively.
Plasma and Serum Preparation
Mice were sedated with 3% isoflurane and blood was collected from the inferior vena cava 
into syringes pre-filled with 3.8% sodium citrate (1 volume of citrate for 9 volumes of 
blood). Mice were then euthanized. Mouse blood was centrifuged at 4,000 × g for 15 
minutes and then at 13,000 × g for 2 minutes to prepare platelet-free plasma. Plasma was 
stored at −80°C until use, while the blood pellet was processed, as stated below. The same 
procedure was applied using syringes without citrate to obtain serum.
Plasma Levels of Thrombin-Antithrombin Complexes (TATc)
Mouse plasma levels of TATc complexes were measured using the Enzygnost TAT micro 
kit (Siemens Healthcare, Marburg, Germany), according to the manufacturer’s instructions.
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Prothrombin Time and Activated Partial Thromboplastin Time
For measuring the prothrombin time (PT) of plasma, 50 µL of PT reagent (Thromboplastin-
D, Pacific Hemostasis, Middletown, VA) was added to 25 µL of plasma and the clotting 
time was measured using a STart4 coagulation analyzer (Diagnostica Stago, Parsippany, 
NJ). For measuring the activated partial thromboplastin time (aPTT) of plasma, 25 µL of 
aPTT reagent (TriniCLOT aPTT S, Tcoag, Wicklow, Ireland) was mixed with 25µL of 
plasma and incubated. Then 25 µL of 0.02 mol/L CaCl2 was added and the clotting time was 
measured using a STart4 coagulation analyzer.
Measurement of Plasma Thrombin Generation
Plasma thrombin generation was measured in 6-fold diluted murine plasma by calibrated 
automated thrombography as described [25]. Reactions were performed in the absence and 
presence of rabbit thrombomodulin (20 nmol/L, Haematologic Technologies, Essex 
Junction, VT) to detect alterations in procoagulant and anticoagulant (protein C/S) pathways 
[3, 6, 26]. Thrombin generation parameters were calculated using Thrombinoscope software 
version 3.0.0.29 (Thrombinoscope BV, Maastricht, Netherlands).
MP TF Activity Assay
MP TF activity was measured as described [27]. Briefly, plasma MPs were pelleted at 
20,000 g for 30 minutes at 4°C, washed three times and resuspended in HBSA buffer (137 
mmol/L NaCl, 5.38 mmol/L KCl, 5.55 mmol/L glucose, 10 mmol/L HEPES, 0.1% bovine 
serum albumin, pH 7.5). For measurement of TF-specific activity, samples were then 
incubated with either an inhibitory rat anti-mouse TF monoclonal antibody (1H1, 100 
µg/mL, kindly provided by Dr. Daniel Kirchhofer, Genentech), or a rat IgG control (Sigma 
Aldrich) for 15 minutes at room temperature. Next, 4.88 nmol/L mouse FVIIa, 146 nmol/L 
human FX, and 10 mmol/L CaCl2, were added to the sample and incubated for 1 hour at 
37°C in a 96-well plate. FXa levels were determined using the chromogenic substrate, 
Pefachrome FXa 8595 (4 mmol/L; Pentapharm, Basel, Switzerland). Absorbance (at 405 
nm) was determined using a SpectraMax M5 and analyzed using Softmax Pro v 5.2C 
software (Molecular Devices, Sunnyvale, CA). TF activity was determined from a standard 
curve generated with recombinant human relipidated TF (0–14 pg/mL, Innovin®, Dade 
Behring). TF-specific activity was determined by subtracting the activity in the presence of 
the blocking antibody from the activity in the presence of the IgG control.
White blood cell (WBC) TF Activity
WBC were isolated from blood as described [14]. The cell pellet was resuspended in 200 µL 
of HBSA buffer and diluted 1:20 before adding to the TF activity assay described above for 
the MP TF assay and incubated for 15 minutes.
Liver Procoagulant Activity
The procoagulant activity of liver tissue lysates was measured using a 1-stage clotting assay 
with a Start4 coagulation analyzer as described [16]. Briefly, frozen liver tissue was 
homogenized in 15 mmol/L n-Octyl-β-D-glycopyranoside and 25 mmol/L HEPES buffer 
(10 mg tissue/ 100 µL buffer) for 30 seconds. Samples were incubated at 37°C for 15 
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minutes. For the clotting assay, 25 µL of sample was incubated with 25 µL of pooled mouse 
plasma for 1 minute, then 25 µL of CaCl2 (20 mmol/L) was added and clotting time was 
measured. The procoagulant activity of the sample was calculated by reference to a standard 
curve generated using recombinant human relipidated TF Innovin (Dade Behring), then 
normalized to the total protein concentration determined using the DC protein assay (Bio-
Rad, Hercules, CA). We have previously found that the anti-mouse TF antibody 1H1 (50 
µg/mL) reduced the procoagulant activity by ~90% [28]. It should be noted that MP, WBC 
and liver TF activity in the different mouse strains were measured over a period of 2 years 
with different batches of reagents and this may explain some of the observed variations 
between experiments.
Western Blotting
Liver tissue samples were homogenised in RIPA lysis puffer supplemented with proteinase 
and phosphatase inhibitors (Roche; Santa Cruz Biotechnologies). Thirty µg of total liver 
tissue protein was diluted in NuPage LDS sample Buffer (Life Technologies), boiled for 5 
minutes, and then applied to 4%–20% Tris-Glycine gels (Bio-Rad Laboratories) to separate 
proteins using electrophoresis. Proteins were transferred to PVDF membranes (Millipore), 
and membranes were blocked for 1 hour with Odyssey blocking buffer (LI-COR 
Biosciences). Primary antibody against mouse TF (1:500 dilution, clone AF3178, R&D 
systems) was incubated overnight at 4°C. Primary antibody was detected by fluorescence-
labelled secondary antibodies (1:10,000 dilution) for 1 hour and membranes analysed using 
an Odyssey Infrared Imaging System (LI-COR Biosciences).
Interleukin 6 ELISA
Mouse interleukin 6 (IL-6) levels were determined using mouse IL-6 Quantikine ELISA Kit 
(RnD Systems), according to the manufacturer’s instructions.
Assessment of Liver Injury and Fibrosis
Measurements of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
levels were performed at the Animal Clinical Laboratory Core Facility, University of North 
Carolina at Chapel Hill, by using an automated blood chemical analyzer VT350 (Ortho-
Clinical Diagnostics Company, Rochester NY). Hepatic collagen content was analyzed by 
Sirius red staining of paraffin-embedded sections. The area of Sirius red staining was 
determined in a cross-section of the entire left lateral liver lobe using virtual microscopy and 
automated analysis with Image J, as described [29].
Gene Expression Analysis
cDNA synthesis was performed with iScript™ RT Supermix (Bio-Rad, Hercules, CA). PCR 
was performed on a realplex2 Mastercycler (Eppendorf, Hamburg, Germary) with the use of 
SSoFast™ Probes Supermix (Bio-Rad). Mouse Ribosomal Protein L4 (Rpl4) was used to 
normalize sample amplification. The primers used were purchased from Integrated DNA 
Technologies (Coralville, IA) and described in Supplementary Table 1. Relative expression 
was calculated using the 2-delta-delta CT method.
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Fibrin staining
Paraffin sections (4 µm thick) were subjected to antigen retrieval (10 mmol/L citrate buffer, 
pH 6.0) for 25 minutes at 95°C. Endogenous peroxidase and endogenous biotin were 
blocked using hydrogen peroxide (3%) and avidin/biotin blocking kit (Vector Laboratories), 
respectively. Sections were incubated with mouse IgG per the mouse-on-mouse biotinylated 
anti-Mouse IgG reagent (Vector Laboratories), and staining for fibrin was performed using 
mouse anti-human fibrinogen antibody (dilution 1:1000 ; gift from Dr. C Esmon, Oklahoma 
Medical Research Foundation) [30]. Subsequently, sections were incubated with the mouse-
on-mouse biotinylated anti-Mouse IgG reagent, followed by Vectastain ABC kit reagents 
(Vector Laboratories). Slides were developed using ImmPACT DAB Peroxidase substrate 
(Vector Laboratories) and counterstained with hematoxylin (Dako). Fibrin staining was 
graded in a blinded fashion for fibrin deposition by using a scale from 0 (no deposition) to 4 
(abundant fibrin signal).
Statistics
Quantitative variables were expressed as median (interquartile range) and categorical 
variables as absolute and relative frequencies. Comparisons between 2 groups of 
independent quantitative variables were performed using non parametric Mann-Whitney U 
test. Comparisons between 3 groups of independent quantitative variables were performed 
using one-way analysis of variance, and the Student- Newman-Keuls post hoc test. All tests 
were two-sided and significance was assigned by P < 0.05. Data handling and analysis were 
performed with SPSS 17.0 (SPSS Inc., Chicago, IL).
Results
Activation of Coagulation in BDL Mice
We analysed mice 12 days after BDL based on our data from time course experiments and 
previous studies [31–32]. The serum AST and ALT levels were markedly elevated in the 
BDL-injured mice (Supplementary Fig. 1A and B), indicating hepatic parenchymal cell 
injury. We observed evidence of chronic injury in the livers of BDL-injured mice with a 
significant increase in expression of the fibrogenic-related genes transforming growth factor 
beta 1, collagen-1α1 and collagen-3α1 and in collagen deposition (Supplementary Fig. 1 C–
G). Furthermore, BDL-injured mice had increased levels of serum IL-6 compared to sham 
mice, indicating an increase in inflammation (Supplementary Fig. 1H).
Next, we analyzed coagulation changes in these mice. BDL mice had prolonged PT, aPTT 
(Fig. 1A–B). In the absence of thrombomodulin, endogenous thrombin potential was not 
different between BDL and sham mice [728 (663–958) vs. 944 (453–1294) nM*min; 
p=0.93]. However, a resistance to thrombomodulin was observed in BDL mice (Fig. 1C). 
Liver injury was associated with an activation of coagulation demonstrated by a significant 
increase in TATc levels (Fig. 1D). There was also an increased fibrin deposition in the liver 
in BDL mice, mainly in areas of hepatic necrosis (Fig. 1E–F).
We also measured levels of WBC TF as well as MP TF activity in the plasma. We found 
that WBC and MP TF activities were both increased in mice subjected to liver injury (Fig. 
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2A and B). We also determine the TF activity per WBC because the WBC count increases 
after BDL. The increase in WBC TF activity was also significant when expressed as TF 
activity per WBC (data not shown). Finally, we measured TF mRNA, activity and protein in 
the liver. BDL did not increase TF mRNA expression, TF activity or protein (Fig. 2C–E). 
However, it should be noted that the activity assay cannot distinguish between encrypted 
and de-encrypted TF in vivo since it uses detergent to de-encrypt TF in the liver.
TF Contributes to the Activation of Coagulation in BDL-injured Mice
We next investigated the role of TF in the activation of coagulation after BDL using low TF 
mice. Importantly, activation of coagulation was significantly attenuated in BDL-injured 
low TF mice compared with TF+/− and TF+/+ mice (Fig. 3A). In TF+/− and low TF mice, the 
median WBC TF activity was 45% and 10% of TF+/+ mice, respectively (Fig. 3B). MP TF 
activity was undetectable in low TF mice and was 26% in TF+/− mice compared with the 
level observed in TF+/+ mice (Fig. 3C). The median liver TF activity in low TF mice was 
18% of TF+/− mice (Fig. 3D). We did not observe any difference in the serum levels of AST 
or ALT, or in expression of profibrogenic genes or in hepatic collagen deposition or in 
serum levels of IL-6 (Supplementary Fig. 2A–G). These data indicate that TF plays a major 
role in the activation of coagulation in BDL-injured mice. However, a deficiency of TF does 
not affect inflammation, liver injury or fibrosis in this model.
Myeloid Cell TF does not Contribute to the Activation of Coagulation in BDL-injured Mice
Monocytes from patients with cirrhosis express TF [17–19] and WBC TF activity is 
increased in BDL-injured mice (Fig. 2A). Therefore, we determined the role of myeloid cell 
TF in the activation of coagulation in the BDL model. We performed BDL on TFflox/flox, 
LysMCre and on TFflox/flox (control) mice. We did not observe any difference in coagulation 
activation (Fig. 4A) but, as anticipated, TFflox/flox, LysMCre mice had reduced WBC TF 
activity (Fig. 4B). However, MP TF activity was not decreased in TFflox/flox, LysMCre mice 
(Fig. 4C). There was no change in liver TF activity in TFflox/flox, LysMCre mice (Fig. 4D). 
Serum aminotransferase activity was slightly higher in TFflox/flox, LysMCre than in 
TFflox/flox mice, but there was no difference in liver fibrosis (Supplementary Fig. 3A–C). In 
addition, we did not observe any difference in the serum levels of IL-6 (Supplementary Fig. 
3D). These results indicate that myeloid cell TF does not play a major role in the activation 
of coagulation in the BDL model.
Hepatocyte TF Contributes to the Activation of Coagulation in BDL-injured Mice
We next investigated the role of hepatocyte TF in the activation of coagulation after BDL 
using TFflox/flox, AlbCre and TFflox/flox (control) mice. Importantly, activation of coagulation 
was significantly attenuated in BDL-injured TFflox/flox, AlbCre mice compared with 
TFflox/flox mice (Fig. 5A). In addition, TFflox/flox, AlbCre mice had reduced liver fibrin 
deposition, MP TF activity and liver TF activity (Fig. 5B, C, E and F). As anticipated, we 
did not find any difference in WBC TF activity in TFflox/flox, AlbCre mice (Fig 5D). We did 
not observe any difference in the serum levels of AST, ALT, or in expression of fibrogenic-
related genes or in the liver fibrosis or in serum levels of IL-6 (Supplementary Fig. 4A–G). 
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These data indicate that hepatocyte TF plays a major role in the activation of coagulation in 
BDL-injured mice, without affecting inflammation or liver injury in this model.
Discussion
A major finding of this study was that TF contributes to the activation of coagulation in a 
model of chronic liver disease. Although TF is the main initiator of the coagulation cascade, 
its role in the hypercoagulable state associated with chronic liver disease had not been 
studied in detail. Indeed, the concept of hypercoagulable state in chronic liver disease is 
based on thrombin-generation tests on plasma samples performed in the presence of 
thrombomodulin or snake-venom extract (Protac, Pentapharm) [1, 3–6]. This assay triggered 
a rethinking of the alternations in the coagulation system associated with chronic liver 
disease. However, there are several limitations with this approach. This assay uses platelet-
free plasma. Therefore, it does not measure TF in blood cells or TF expressed by cells in 
organs, such as hepatocytes [17]. Moreover, exogenous TF is added to the plasma to trigger 
coagulation and, although at low concentration, this likely overwhelms any endogenous MP 
TF activity in the plasma [33]. The novelty of our approach is the use of genetically 
modified mice to examine the role of TF in vivo in a mouse model that reproduces 
coagulation changes associated with chronic liver disease and cirrhosis, including prolonged 
PT and aPTT, resistance to thrombomodulin, activation of coagulation and increases in 
WBC and MP TF activities [1, 17–19, 34]. A practical consequence of these findings could 
be that strategies aimed at reducing TF deencryption may decrease thrombosis risk in 
patients with advanced cirrhosis [35].
A second major finding of this study was that hepatocyte TF is the major source for 
activation of coagulation in chronic liver disease (Fig. 6). In wild-type mice, liver TF 
activity was not different between BDL-injured and sham mice. This result was anticipated 
because the assay uses a cell lysis step that activates all the liver TF [23]. Therefore, the 
assay does not distinguish between encrypted (non-active) and deencrypted (active) TF. We 
found here that genetically reducing TF expression in all cells, and selectively in 
hepatocytes, reduced liver TF activity and activation of coagulation in BDL-injured mice. 
Although the liver expresses relatively low levels of TF compared to other organs/tissues,
[36] it is a prominent source of procoagulant TF in chronic liver injury, as observed in acute 
liver diseases [23, 37]. We have previously demonstrated that hepatocytes express TF that 
lacks detectable procoagulant activity in the healthy liver [23]. However, hepatocyte injury 
triggers hepatocyte TF-dependent activation of coagulation in mice. Of importance, 
activation of coagulation by hepatocyte TF would not require increased TF expression. 
Rather, this could occur via molecular activation of the existing TF:FVIIa complex. This is 
consistent with our finding that total liver TF activity did not increase after BDL.
BDL-injured mice displayed elevated WBC TF activity, recapitulating the increase in 
monocyte TF activity reported in patients with cirrhosis [17–19]. However, we found that a 
deficiency of TF in myeloid cells did not reduce activation of coagulation after BDL. This 
lack of effect of myeloid TF on activation of coagulation is in agreement with a previous 
study showing that myeloid cell TF deficiency does not affect coagulation activation after 
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acute cholestatic liver injury [38]. These results suggest that WBC TF activity is not a 
prominent contributor to the activation of coagulation in chronic liver disease.
The third major finding of this study was that hepatocytes are the source of the increase in 
MP TF activity observed in BDL-injured mice. This observation indicates that injured 
hepatocytes could be a prominent source of procoagulant MPs in patients with chronic liver 
disease. We previously found that MP TF activity is elevated in patients with cirrhosis and 
increases with cirrhosis severity [34]. In patients, we could not determine the cellular origin 
of TF+ MP because the low levels of TF present on the MPs could not be detected by flow 
cytometry. Nevertheless, we examined the correlations between MP TF activity and plasma 
levels of the specific MP subtypes in patients with cirrhosis. MP TF activity correlated with 
circulating levels of hepatocyte MPs (Cytokeratine-18+ MPs) (Spearman r = 0.377; p = 
0.031; n=33), but not with leukocyte MPs levels (unpublished data). These unpublished data 
obtained in patients with cirrhosis support our findings obtained in mice. Hepatocytederived 
circulating MPs are also observed in acute liver injury [37]. We can speculate that an 
increase in hepatocyte-derived, TF-positive MPs may predict venous thrombosis events, 
including portal vein thrombosis in patients with chronic liver disease and cirrhosis.
We did not observe any effect of TF deficiency on expression of profibrogenic genes or on 
hepatic collagen deposition in the BDL model. This allowed us to investigate the mechanism 
of activation of coagulation associated with chronic liver disease without being biased by an 
effect on fibrosis. We were initially surprised that there was not a reduction in fibrosis in 
low TF mice since a previous study found that heterozygous TF deficiency exhibited 
reduced hepatic fibrosis in experimental biliary hyperplasia induced by α-
naphthylisothiocyanate [39]. However, despite the observation that protease activated 
receptor 1 inhibition reduces liver injury after BDL [40], other thrombin-driven processes, 
including platelet activation and fibrin deposition, have been shown to exert 
hepatoprotective effects in the context of cholestatic liver damage [29, 41]. These results 
suggest that the association of TF-driven coagulation with liver pathology is dependent on 
the experimental model.
In conclusion, our results demonstrate that hepatocyte TF contributes to the activation of 
coagulation in a mouse model of chronic liver disease. These data suggest that TF may 
contribute to the hypercoagulable state and thrombotic events in patients with chronic liver 
disease.
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Figure 1. Activation of coagulation in mice with chronic liver injury
Bile duct ligation (BDL) or sham surgery was performed in C57BL/6 mice. (A–C) Twelve 
days after surgery we measured prothrombin time (PT) and activated partial thromboplastin 
time (aPTT), as well as the ratio of the values of endogenous thrombin potential (ETP) 
obtained without and with thrombomodulin (TM) We also measured plasma levels of 
thrombin-antithrombin complexes (TATc) (D) and liver fibrin deposition (E, quantification; 
F, representative images).
Data are given as median (horizontal bar), 25th and 75th percentile (error bar).
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*, p<0.05; **, p<0.01; ***, p<0.001.
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Figure 2. Tissue factor expression in mice with chronic liver injury
White blood cell (A) and MP (B) TF activities were determined in C57BL/6 mice after BDL 
or sham surgery. We also measured TF mRNA, activity and protein in the liver of these 
mice (C–E). For western blot (E), we used lung as a positive control.
Data are given as median (horizontal bar), 25th and 75th percentile (error bar).
Abbreviations: BDL, Bile Duct Ligation; MP, microparticle; ns, not significant; TF, tissue 
factor; WBC, white blood cell.
**, p<0.01; ***, p<0.001.
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Figure 3. Tissue factor contributes to activation of coagulation in mice with chronic liver injury
BDL was performed in mice expressing 1% (low TF mice), 50% (TF+/− mice) and 100% 
(TF+/+) of wild-type TF levels. Plasma levels of TATc were measured (A). White blood cell 
(B), MP (C) and liver (D) TF activities were determined.
Data are given as median (horizontal bar), 25th and 75th percentile (error bar).
Abbreviations: BDL, Bile Duct Ligation; MP, microparticle; TATc, thrombinantithrombin 
complexes; TF, tissue factor; WBC, white blood cell.
*, p<0.05; **, p<0.01; ***, p<0.001. Only significant differences are shown.
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Figure 4. Myeloid tissue factor does not contribute to activation of coagulation in mice with 
chronic liver injury
BDL was performed in TFflox/flox, LysMCre and in TFflox/flox mice. Plasma levels of TATc 
were measured (A). White blood cell (B), MP (C) and liver (D) TF activities were 
determined.
Data are given as median (horizontal bar), 25th and 75th percentile (error bar).
Abbreviations: BDL, Bile Duct Ligation; MP, microparticle; ns, not significant; TATc, 
thrombin-antithrombin complexes; TF, tissue factor; WBC, white blood cell. ***, p<0.001.
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Figure 5. Hepatocyte tissue factor contributes to activation of coagulation in mice with chronic 
liver injury
BDL was performed in TFflox/flox, AlbCre and in TFflox/flox mice. Plasma levels of TATc 
were measured (A). Liver fibrin deposition was assessed (B, quantification; C, 
representative images). White blood cell (D), MP (E) and liver (F) TF activities were 
determined.
Data are given as median (horizontal bar), 25th and 75th percentile (error bar).
Abbreviations: BDL, Bile Duct Ligation; MP, microparticle; ; ns, not significant; TATc, 
thrombin-antithrombin complexes; TF, tissue factor; WBC, white blood cell.
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*, p<0.05; **, p<0.01; ***, p<0.001.
Rautou et al. Page 19
J Hepatol. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 6. Potentital sources of tissue factor (TF) that may activate coagulation in chronic liver 
disease
We propose that under normal condition, hepatocyte TF is cryptic. In chronic liver diseases, 
hepatocyte TF is actived and contributes to the activation of coagulation and liver fibrin 
deposition. Myeloid cell TF activity is increased in liver injury, but is not a prominent 
contributor to the systemic activation of coagulation. Microparticle (MP) TF activity is 
increased in cirrhosis. However, we cannot determine the relative contribution of hepatocyte 
TF versus MP TF to the activation of coagulation.
Full and dashed lines indicate likely and potential links, respectively.
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